UBS Group Analysts Give Novartis (NOVN) a CHF 83 Price Target

Novartis (VTX:NOVN) has been given a CHF 83 target price by equities researchers at UBS Group in a research note issued to investors on Thursday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock.

NOVN has been the subject of several other research reports. Morgan Stanley set a CHF 80 price objective on shares of Novartis and gave the stock a “sell” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. set a CHF 85 price objective on shares of Novartis and gave the stock a “sell” rating in a research report on Tuesday, April 9th. Credit Suisse Group set a CHF 84 price objective on shares of Novartis and gave the stock a “neutral” rating in a research report on Friday, April 5th. HSBC set a CHF 86 price objective on shares of Novartis and gave the stock a “neutral” rating in a research report on Wednesday, February 6th. Finally, Deutsche Bank set a CHF 96 price objective on shares of Novartis and gave the stock a “neutral” rating in a research report on Wednesday, January 30th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of CHF 88.35.

Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.



About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: How to calculate the annual rate of depreciation

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.